

8 PUBLIKATIONSVERZEICHNIS

8.1 Originalarbeiten

2007:

Baradari V, Höpfner M, Huether A, Schuppan D und Scherübl H (2007).
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
World J Gastroenterol 13(33): 4458-4466.

Huether A, Höpfner M, **Baradari V**, Schuppan D und Scherübl H (2007).
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Biochem Pharmacol 73(9):1308-1317.

2006:

Baradari V, Huether A, Höpfner M, Schuppan D und Scherübl H (2006).
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Endocr Relat Cancer 13(4):1237-1250.

Höpfner M*, **Baradari V***, Huether A, Schöfl C und Scherübl H (2006).
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Endocr Relat Cancer 13(1):135-149.

* both authors contributed equally to this work

Höpfner M, Sutter AP, Huether A, **Baradari V** und Scherübl H (2006).
Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
World J Gastroenterol 12(35):5635-5643.

Höpfner M, Huether A, Sutter AP, **Baradari V**, Schuppan D und Scherübl H (2006).
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Biochem Pharmacol 71(10):1435-1448.

Huether A, Höpfner M, Sutter AP, **Baradari V**, Schuppan D und Scherübl H (2006).
Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer.
World J Gastroenterol 12(32):5160-5167.

2005:

Huether A, Höpfner M, **Baradari V**, Schuppan D und Scherübl H (2005).
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
Biochem Pharmacol 70(11):1568-1578.

2003:

Pollok-Kopp B, Schwarze K, **Baradari V** und Oppermann M (2003).
Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in intact cells using phosphosite-specific antibodies.
J Biol Chem 278 (4): 2190-2198.

8.2 Kurzveröffentlichungen und Posterabstracts

Baradari V, Höpfner M, Huether A und Scherübl H (2005).
Specific inhibition of the IGFR tyrosine kinase as a novel approach for targeted therapy in neuroendocrine gastrointestinal tumor disease. *Z Gastroenterol* 43:358.

Höpfner M, Huether A, **Baradari V**, Schuppan D und Scherübl H (2005).
The insulin-like growth factor receptor is a promising target for innovative treatment approaches of hepatocellular cancer. *Z Gastroenterol* 43:357.